Benzinga | Nov 2, 2021 10:52AM EDT

AC Immune Highlights New Data On Investigational Alzheimer's Disease Candidates Will Be Featured In Scientific Program Of 'Clinical Trials On Alzheimer's Disease' Conference Nov. 9-12, 2021

AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announces that new data on its investigational Alzheimer's disease (AD) candidates semorinemab, ACI-35.030 and ACI-24 will be featured in the scientific program of the Clinical Trials on Alzheimer's Disease (C-TAD) Conference, taking place virtually and in person in Boston, on November 9-12, 2021.

Scientific updates at CTAD 2021

Semorinemab monoclonal anti-tau antibody

Title: Phase 2 Trial of Semorinemab in Mild-to-Moderate Alzheimer's Disease (Lauriet): Topline results

Presenter: late-breaking readout roundtable by Cecilia Monteiro

Date: Wednesday November, 10 I 10.50am-11.20am EST I In-person session streamed live in the digital platform of CTAD I Available on demand 48 hours after the session

ACI-35.030 Anti-pTau Vaccine

Title: ACI-35.030, a novel anti-phospho-Tau vaccine for the treatment of Alzheimer's Disease: Interim Phase 1b/2a data on safety, tolerability and immunogenicity

Presenter: oral presentation by Johannes Streffer

Date: Friday, November 12 I Available on demand in the digital platform of CTAD from 08:00am EST

ACI-24 anti-beta amyloid vaccine

Title: ACI-24, an anti-beta amyloid vaccine, in patients with mild Alzheimer's disease: Results of a phase 2, randomized, double-blind, placebo-controlled study

Presenter: Poster P44 presented by Olivier Sol

Date: November 9-12 I Available on the digital platform of CTAD at all times